ginning treatment. Thereafter, levels promptly declined, reaching near baseline within 24 hours despite continuation of IL-6. TNFsRp55 plasma levels increased within 4 to 8 hours after initiating treatment and increased progressively throughout the duration of therapy. IL-lB and TNF-a plasma levels were below the detection limit in all samples tested. Peripheral blood mononuclear cells NTERLEUKIN-6 (IL-6) is a pleiotropic cytokine involved in the regulation of immune responses, the acute-phase reaction, and hematopoiesis.' This cytokine is produced by a variety of cells after stimulation, such as occurs with infection, trauma, or immunological challenge. IL-6 has a protective role in the lipopolysaccharide (LPS)-galactosamine septic shock model in mice.' It also suppresses the acute neutrophil exudation caused by an intratracheal instillation of endotoxin in rats. 3 Tumor necrosis factor-a (TNF-a) levels measured in the bronchoalveolar fluid of these animals were also significantly reduced. Earlier studies showed that IL-6 inhibits LPS-induced TNF-a and IL-l/3 production in cultured human monocytes, U937 cells, and in mice in v~v o .~.~ Together, these data suggest that IL-6 possesses antiinflammatory properties.
IL-1 receptor antagonist (IL-1Ra) is a member of the IL-1 family that antagonizes the effects of both IL-la and IL-18 by blocking the binding of IL-1 to cell surface recept o r~.~, ' IL-1 Ra has protective effects against several IL-lmediated pathological processes, such as septic shock, inflammatory bowel disease, and others:. ' Several cytokines have been demonstrated to induce IL-1 Ra synthesis, including IL-1, IL-2, IL-4, interferon alfa, interferon gamma, granulocyte-macrophage colony stimulating factor (GM-CSF), and transforming growth factor-p (TGF-p). 8"3 Naturally occumng TNF antagonists have been identified in the urine of patients with various febrile condit i o n~. '~' '~ These inhibitors were subsequently shown to represent the extracellular part of the two known TNF receptors (p55 and p75) and have therefore been designated soluble TNF receptors p55 and p75 (TNFsRp55 and TNFsRp75).I6-l9 Soluble forms of both TNF receptors block LPS-mediated lethality in animal models, particularly when administered as IgG fusion proteins.20.2'
The present study was undertaken to determine whether IL-6 immunotherapy in humans is associated with circulating IL-l and TNF antagonists and to determine the likely cells of origin of these mediators.
I
Blood, Vol83, No 1 (January l ) , 1994: pp 1 13-1 18 (PBMC) exposed to IL-6 produced only small amounts (1.56 f 0.3 ng/mL) of IL-l Ra, even in the presence of exogenous soluble IL-6 receptor (gp80). TNFsRp55 levels measured in the supernatants of IL-6-stimulated PBMC were below the detection limit of the assay. Macrophages generated by culturing monocytes in granulocyte-macrophage colony-stimulating factor (GM-CSF) were much more responsive to IL-6 than freshly isolated unfractionated or adherent PBMC and synthesized almost as much IL-lRa when stimulated with IL-6 as with endotoxin. These results suggest that the antiinflammatory properties of IL-6 may be due, in part, to the induction of IL-l Ra synthesis and the release of soluble TNF receptors. Our findings also suggest that tissue macrophages may be an important source of IL-6-induced IL-l Ra.
0 1994 by The American Society of Hematology.
MATERIALS AND METHODS

Clinical materials.
Patients who participated in this study were enrolled in phase I and I1 trials performed by the Cytokine Working Group. These clinical trials were approved by the Human Investigation Review Committee at the New England Medical Center, and all study participants gave written, informed consent. Israel. Recombinant GM-CSF was purchased from lmmunex (Seattle, WA). LPS (from Escherichia coli 055:B5), HEPES, and FicollHypaque were obtained from Sigma Chemical (St Louis, MO). RPMI 1640 medium was purchased from GIBCO (Grand Island, NY), streptomycin from Irvine Scientific (Santa Ana, CA), and fetal bovine serum (FCS) from Hyclone Laboratories (Logan, UT). Dexamethasone was obtained from American Regent Laboratories (Shirley, NY). Polyethylene glycol 8000 was purchased from Fisher Scientific (Fair Lawn, NJ) and polymyxin B sulfate from Pfizer (New York, NY).
I.solation of peripheral blood mononuclmr cells (PBMC). PBMC for in vitro studies were isolated from the heparinized blood of healthy volunteers and IL-6-treated patients by density centrifugation through Ficoll-Hypaque. The cells were washed twice in sterile saline, and then incubated in polypropylene tubes at a density of 2.5 X IO6 cells/mL in RPMI 1640 medium supplemented with I O mmol/L HEPES, 2 mmol/L L-glutamine. 100 U/mL penicillin, 100 wg/mL streptomycin, and 5% heat-inactivated FCS, henceforth referred to as complete medium. In all experiments, except those with endotoxin, 5 pg/mL of polymyxin B was used. PBMC were incubated in polypropylene tubes for 24 hours at 37°C in a humidified atmosphere containing 5% CO2, then freeze-thawed three times. Cytokine data therefore reflect the total amount of IL-Ra produced (secreted and cell-associated). PBMC from four patients receiving a continuous IL-6 infusion were isolated on day 1 immediately before therapy start and on day 3 (48 hours).
In vitro generution o f mucrophuges jrom monocytes. Macrophages were prepared from PBMC as recently reported by Janson et aL2' Monocyte-enriched cells were obtained by incubating PBMC in complete medium in plastic flasks (75 cm2, polystyrene; Corning, New York, NY) for 60 minutes at 37°C and then separating the adherent from nonadherent cells. Adherent cells were more than 80% positive for Leu-M3 (CD14; Becton Dickinson, Mountain View, CA) by cytofluorographic analysis. Adherent monocytes (5 X IO6 cells) were then cultured in 5 mL of complete medium supplemented with 500 U/mL recombinant GM-CSF for 6 days. The culture medium was replaced with fresh medium on day 3.
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TlLG ET AL were quantitated with specific radioimmunoassays (RIAs) as previously described. The RIA for IL-I Ra is unaffected by the presence of IL-10'' and the IL-1 0 assay is not influenced by IL-I Ra." Likewise, the RIA for TNF-a is not affected by T N F s R~~~*~ and the RIA for TNFsRp55 is unaffected by TNF-a." A glycosylated form of TNFsRp55 expressed in Chinese hamster ovary cells was used to immunize New Zealand white rabbits in the generation of the antiTNFsRp55 antibody used in the RIA." This glycosylated form of TNFsRp55 was also used to generate the standard curve for the RIA. The limit of detection was 80 to 160 pg/mL for all RIAs used. Slalistics. All results are shown as the mean f SEM. Student's I-test was used to determine statistical significance. TNFsRp55 levels during IL-6 immunotherup.v. Six patients with advanced malignancy were studied. Before therapy, plasma IL-1 Ra levels in the patients were slightly, but not significantly, elevated compared with those of healthy controls (0.4 1 f 0.07 v 0.29 f 0.08 ng/mL, n = IO). Levels increased rapidly, reaching a peak of 9.6 -+ I .7 ng/mL within 2 to 4 hours of initiating the 1L-6 infusion (Fig l) . Thereafter, levels gradually declined to nearly baseline values within 24 hours (0.67 -+ 0.14 ng/mL). Levels remained slightly elevated compared with pretreatment values until the end of therapy.
RESULTS
Plusma IL-IRu und
Pretreatment TNFsRp55 levels were significantly higher in patients than in healthy controls (3.2 f 0.4 v 1.4 f 0.2 ng/ mL, n = IO; P < .05). Levels increased within 4 hours of beginning treatment and thereafter increased continuously until the end of the 120-hour infusion. Peak levels (12.2 i 1.5 ng/mL) were observed on day 5 (Fig 2) . IL-I@ and TNF-Q: levels were assayed at the same time points as the 1L-I Ra and TNFsRp55 measurements and were consistently below the detection limit of the assays (data not shown). For in the supernatants were below the detection limit of the assay (data not shown). IL-6 was a weak inducer of IL-1 Ra synthesis, yielding levels rarely in excess of 1.5 ng/mL, even with high IL-6 concentrations (100 ng/mL) (Fig 3A) . In the same experiments, LPS (10 ng/mL) induced 8.3 f 1.3 ng/ mL of IL-l Ra. IL-6 (10 ng/mL) did not enhance the response to LPS at LPS concentrations of 0.1 ng/mL or greater (Fig 3B) . Even the modest enhancement apparent with low LPS concentrations was not statistically significant. On the other hand, neither did IL-6 suppress LPS-induced IL-1Ra production as previously demonstrated for LPS-induced IL-1 and TNF
I12-h-induced IL
The weak response of PBMC to IL-6 could have been due to a lack of IL-6 receptors (gp80). In circumstances in which a low level of gp80 expression limits IL-6 signaling, exogenous sIL-6R has been shown to enhance the response to this cytokine. For example, sIL-6R augments IL-6-induced acute-phase protein synthesis by hepatocyte^.^' However, this truncated receptor had no effect on IL-6-induced IL-1 Ra synthesis by PBMC at sIL-6R concentrations of up to 500 ng/mL (data not shown), suggesting that gp80 expression was not a limiting factor in IL-6-induced IL-1 Ra synthesis. The poor response to IL-6 was also not due to a dependency on glucocorticoids. Whereas IL-6-induced acute-phase protein synthesis by hepatocytes is steroid-dependent,28 glucocorticoids (lo" mol/L dexamethasone) actually suppress IL-6-induced IL-l Ra production by PBMC (data not shown). PBMC from four of six patients treated with a 5-day continuous IL-6 infusion were isolated before therapy and on day 3. Unstimulated PBMC obtained before treatment from these patients produced significantly more IL-1Ra (2.95 k 0.97 ng/mL) than did PBMC from healthy controls (0.5 k 0.1 ng/mL, n = 8; P < .01). Despite increased constitutive production, PBMC from the cancer patients were refractory to stimulation with IL-6 alone or in combination with sIL-6R (Fig 4) . The response to LPS was comparable to that of PBMC from healthy donors. Constitutive production of IL- Production of IL-l Ra by PBMC isolated from four patients treated with IL-6. PBMC were isolated before therapy start (U) and on day 3 (48 hours) (9. IL-6 was used at a concentration of 10 ng/ mL, slL-6R at 100 ng/mL. and LPS at 100 ng/mL. Data are presented as the mean 2 SEM. *P < .05 compared with baselines (no
IL-6).
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Fig 5. Production of IL-l Ra by GM-CSF-primed macrophages (U) and freshly isolated adherent PBMC (B). Macrophages from three donors were prepared as described in
Materials and Methods. IL-l Ra RIA was performed with cell lysates as described in Materials and Methods. IL-6 was used at a concentration of 1 0 ng/mL, slL-6R at 100 ng/mL, and LPS at 100 ng/mL. course was even greater than that of pretreatment PBMC. As with the pretreatment cells, those obtained on day 3 were unresponsive to stimulation with IL-6 alone or in conjunction with sIL-6R (Fig 4) .
IL-&induced IL-1Ra synthesis by GM-CSF-primed macrophages. We studied the possibility that macrophages, rather than monocytes, could synthesize IL-I Ra in response to IL-6. Macrophages (5 X lo6 cells) were obtained by culturing monocytes from healthy donors in GM-CSFcontaining medium for 6 days. After three washes, cells were incubated for 24 hours in medium alone or medium containing IL-6, sIL-~R, IL-6 plus sIL-~R, or LPS. As shown in Fig 5, macrophages synthesized more IL-I Ra than did equal numbers of freshly isolated adherent PBMC from the same donors (P < .001). Furthermore, these cells were highly responsive to IL-6, generating as much IL-1 Ra in response to this cytokine (46.2 f 4.3 ng/mL) as they did to LPS (50.3 f 3.8 ng/mL). As with PBMC, the addition of sIL-6R to the cultures did not further enhance IL-6-induced IL-1 Ra production.
DISCUSSION
Cytokines such as IL-4, IL-IO, and tumor growth factor-@ (TGF-@) exert their antiinflammatory effects, in part, by suppressing IL-1 and TNF synthesis.29 IL-4 and TGF-@ are also potent inducers of IL-lRa, which may contribute to their antiinflammatory actions by neutralizing the biological effects of IL-1 .8*13 Our results indicate that IL-6 belongs to this category of antiinflammatory cytokines, which both suppress IL-1 and TNF synthesis and induce the production or release of IL-l and TNF antagonists.
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Measurements of IL-1 Ra levels during an IL-6 infusion showed an unexpected pattern. Levels promptly increased and then rapidly declined to nearly baseline levels, despite continuing the IL-6 infusion. In contrast, plasma IL-lRa levels in patients receiving repeated bolus injections of IL-2 remain persistently elevated throughout the treatment c o u r~e .~
The reason for the rapid decline in IL-1Ra levels despite continuous IL-6 administration is not clear. The administration of IL-6 results in the release of glucocortic o i d~.~~ The release of endogenous hydrocortisone has been shown to limit the levels of circulating TNF3' and IL-632 resulting from an injection of LPS. and it is likely that a similar process is responsible for the kinetics of IL-1 Ra release induced by IL-6. The contention that endogenous steroids may be involved in this short-lived increase in IL-1 Ra levels is further supported by our finding that IL-6-induced IL-l Ra synthesis in PBMC is completely abolished by dexamethasone. An alternative explanation for the rapid decline in IL-1Ra levels could be the downregulation of the IL-6-binding subunit (gp80) of IL-6R, which has been demonstrated to occur in hepatoma cells in response to IL-6.'3 However, low levels of membrane gp80 may not appreciably compromise IL-6 responses in vivo, as sIL-6R present in plasma34 may be able to substitute for the membrane-bound receptor in cells in which gp80 expression is limited. This is in fact the case with hepatocytes in which exogenous sIL-6R has been shown to augment IL-6-induced acute-phase protein ~ynthesis.~'
The constitutive production of IL-1 Ra by PBMC isolated on day 3 of treatment was much greater than that of pretreatment PBMC. We have recently shown that acute-phase proteins such as C-reactive protein are potent inducers of IL-1Ra synthesis in vitro.35 These are present in high concentrations in the plasma during IL-6 treatment and could be responsible for the enhanced constitutive production of IL-1Ra by PBMC isolated during treatment. The lack of correlation between the increased constitutive production in vitro of IL-I Ra and the low plasma levels is most likely due to high plasma hydrocortisone levels.30
Although transient, the peak plasma levels of IL-1Ra achieved with an IL-6 infusion are similar to those observed after IL-2 or LPS admini~tration.'.~~ However, IL-2 or LPS induces five times more IL-1 Ra than does IL-6 in vitro.','* The basis for this weak in vitro response to IL-6 is unknown. Human monocytes express high numbers of ILdR (g~80).~' Furthermore, IL-6 suppresses LPS-induced IL-l and TNF synthesis in human PBMC.4.5 Together, these data suggest that the weak induction of IL-IRa by PBMC is not likely due to a defect in IL-6 signaling.
Our data suggest that PBMC are most likely not the primary source of the circulating IL-1 Ra in patients undergoing IL-6 treatment. Macrophages produce large amounts of IL-1 Ra, especially when they are GM-CSF-primed." High levels of constitutive IL-l Ra production have also been demonstrated in alveolar macrophages,22 and gut macrophages from healthy people.38 Our data showing that macrophages generated from GM-CSF-primed monocytes synthesize large amounts of IL-l Ra after stimulation with IL-6 or LPS further support the view that tissue macrophages are For personal use only. on September 24, 2017. by guest www.bloodjournal.org From an important source ofthis cytokine antagonist. In our studies, macrophages produced five to 10 times more IL-1Ra than did fresh monocytes, and were highly sensitive to IL-6, indicating that IL-1 Ra production changes during macrophage differentiation both with respect to the quantities synthesized and to the range of inducing agents to which the cells are responsive.
IL-6 is known to enhance the expression ofTNF receptors on hepatoma cells and hepatocyte^.^' We now show that IL-6 immunotherapy is associated with the shedding of TNFsRp55 into the circulation. However, IL-6 failed to induce the release of TNFsRp55 from PBMC in vitro. This lack of in vitro activity has been observed with both PBMC and neutrophils exposed to LPS, IL-l, TNF, and other cytokines that induce high levels of TNFsRp55 when administered in V~V O .~* *~~~
The basis for this discrepancy is so far unexplained. For personal use only. on September 24, 2017. by guest www.bloodjournal.org From
